However, given the substantial differences in the clinical and biological features among thyroid cancer subtypes, assessing the efficacy of BRAF/MEK inhibitor treatments in each subtype in real-world settings is crucial to improve the treatment strategies and define the role of tumor-agnostic therapies in BRAF V600E-positive thyroid cancer. This evidence concerns the gene BRAF and neoplasm.